Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

AGN-211745

Alternative Names: agn-211745, agn211745, agn 211745, sirna-027, sirna 027, sirna027
Latest Update: 2021-04-01
Latest Update Note: PubMed Publication

Product Description

the first chemically modified short interfering RNA (siRNA) targeting Vascular Endothelial Growth Factor Receptor-1  (Sourced from: https://amdbook.org/content/agn-745-sirna-027-wet-amd-development-was-halted)

Mechanisms of Action: VEGFR1 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Choroidal Neovascularization|Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT00395057

P2

Terminated

Choroidal Neovascularization|Macular Degeneration

2008-10-01

SIRNA 0401

P2

Completed

Choroidal Neovascularization|Macular Degeneration

2007-04-01

Recent News Events

Date

Type

Title

04/01/2021

PubMed

 RNA therapeutics in ophthalmology - translation to clinical trials.

02/01/2021

PubMed

 Progress on ocular siRNA gene-silencing therapy and drug delivery systems.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions